On July 11, 2022 Redx (AIM: REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic disease, reported that it will be presenting at the Proactive One2One Virtual Investor Forum on Thursday 14 July 2022 (Press release, Redx Pharma, JUL 11, 2022, View Source [SID1234616574]). The webinar event will begin at 18:00 BST and investors can register to attend here: View Source There will also be the opportunity for investors to ask questions during the event.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Lisa Anson, Chief Executive Officer of Redx, will be presenting an overview of the Company following the recent successful fundraise of £34.3m and strong progress reported at the time of the Company’s Interim Financial Results in June. This included the acceptance of the Investigational New Drug (IND) submission for JZP815, a pan-RAF inhibitor from the Company’s partnership with Jazz Pharmaceuticals. JZP815 is the fifth molecule from the Redx Discovery Engine to enter the clinical stage of development, highlighting the strength of Redx’s worldclass medicinal chemistry expertise and drug discovery capabilities. The presentation will also include updates on the clinical programmes for Redx